Search
BioKangtai Secures Approval for Clinical Trial of Influenza Split Vaccine (BK-01 Adjuvant)
2 day ago /
Read about 0 minute
Author：小编
BioKangtai has garnered approval from the National Medical Products Administration to commence clinical trials for its Influenza Split Vaccine (BK-01 Adjuvant). Tailored for individuals aged 60 and older, this innovative vaccine leverages an adjuvant independently developed by the company to bolster its immunogenicity. Upon successful development, it promises to offer a novel vaccination alternative specifically tailored to the elderly population.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
